Skip to main content

Table 1 LncRNAs expression level and oncological treatment resistance in lung cancer

From: Histone code and long non-coding RNAs (lncRNAs) aberrations in lung cancer: implications in the therapy response

lncRNA Possible targets Mechanism Drug Dysregulation status Lung cancer type Reference
CUDR Caspase 3 N/D Doxorubicin/
Etoposide
Up Squamous carcinoma [68]
HOTAIR p21 N/D Cisplatinum Up NSCLC [65]
  HOXA1 DNA methylation Multidrug resistance (Cisplatinum, Adriamycin, Etoposide) Up SCLC [66]
  Klf4 Promote stemness. Cisplatinum Up NSCLC [67]
AK126698 Wnt/β-catenin, NKD2 N/D Cisplatinum Down NSCLC [55]
MEG3 p53, Bcl-xl N/D Cisplatinum Down NSCLC [62]
  Wnt/β-catenin N/D Cisplatinum Down NSCLC [69]
NEAT1 CTR1 N/D Cisplatinum Down Adenocarcinoma [70]
H19 N/D N/D Cisplatinum Up NSCLC [73]
ROR PI3K/AKT/mTOR N/D Cisplatinum Up NSCLC [71]
  EMT N/D Docetaxel Up NSCLC [72]
CCAT1 let-7c N/D Docetaxel Up Adenocarcinoma [75]
KCNQ1OT1 N/I N/D Paclitaxel Up NSCLC [76]
TUG1 LIMK2b, EZH2 Promoter DNA methylation Multidrug resistance (Cisplatinum, Adriamycin) Up SCLC [74]
  1. Up upregulated, Down downregulated, SCLC small-cell lung cancer, NSCLC non-small cell lung cancer, N/D non-determined